At close: December 13 at 4:00:02 PM EST
After hours: December 13 at 4:00:22 PM EST
Insider Purchases Last 6 Months
| Shares | Transactions | |
|---|---|---|
| Purchases | 0 | 0 |
| Sales | -- | 0 |
| Net Shares Purchased (Sold) | 0 | 0 |
| Total Insider Shares Held | 768.37k | -- |
| % Net Shares Purchased (Sold) | -- | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
| Shares | |
|---|---|
| Net Shares Purchased (Sold) | -- |
| % Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
| Insider | Transaction | Type | Value | Date |
|---|---|---|---|---|
| SCHIMMELPENNINK EVERT B. Chief Executive Officer | Conversion of Exercise of derivative security at price 1.04 per share. | Direct | 46,800 | Jul 22, 2024 |
| CHEVALLARD DANIEL R Chief Financial Officer | Purchase at price 15.68 per share. | Direct | 49,988 | May 14, 2024 |
| MCCOLLUM JAMES W Director | Purchase at price 15.99 per share. | Indirect | 501,093 | May 13, 2024 |
| RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) at price 0.00 per share. | Indirect | 0 | Mar 21, 2024 |
| MCCOLLUM JAMES W Director | Stock Award(Grant) at price 0.00 - 2.15 per share. | Indirect | 35,761 | Mar 21, 2024 |
| ODRICH MARC Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Mar 21, 2024 |
| RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security | Purchase at price 2.15 per share. | Indirect | 2,145,719 | Mar 21, 2024 |
Related Tickers
TARS Tarsus Pharmaceuticals, Inc.
52.50
+2.78%
CNTA Centessa Pharmaceuticals plc
16.57
-1.78%
VRDN Viridian Therapeutics, Inc.
17.85
-0.78%
RNAC Cartesian Therapeutics, Inc.
18.69
-7.13%
RGNX REGENXBIO Inc.
8.28
-5.05%
CLLS Cellectis S.A.
1.7600
-4.86%
CLSD Clearside Biomedical, Inc.
1.0200
+2.00%
STOK Stoke Therapeutics, Inc.
12.06
-2.11%
OCUL Ocular Therapeutix, Inc.
8.69
-2.25%
OKUR OnKure Therapeutics, Inc.
9.86
-8.96%